Switch theme
Sign up to access all valuation multiples
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company has only one segment which is Pharmaceuticals and it operates in domestic market.
1950
1.7K+
LTM Revenue $261M
LTM EBITDA $79.2M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pfizer India has a last 12-month revenue of $261M and a last 12-month EBITDA of $79.2M.
In the most recent fiscal year, Pfizer India achieved revenue of $255M and an EBITDA of $95.1M.
Pfizer India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pfizer India valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $282M | $255M | XXX | XXX | XXX |
| Gross Profit | $193M | $180M | XXX | XXX | XXX |
| Gross Margin | 69% | 71% | XXX | XXX | XXX |
| EBITDA | $110M | $95.1M | XXX | XXX | XXX |
| EBITDA Margin | 39% | 37% | XXX | XXX | XXX |
| Net Profit | $71.1M | $72.5M | XXX | XXX | XXX |
| Net Margin | 25% | 28% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pfizer India's stock price is INR 4080 (or $47).
Pfizer India has current market cap of INR 187B (or $2.2B), and EV of INR 164B (or $1.9B).
See Pfizer India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.2B | XXX | XXX | XXX | XXX | $1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pfizer India has market cap of $2.2B and EV of $1.9B.
Pfizer India's trades at 7.3x LTM EV/Revenue multiple, and 24.1x LTM EBITDA.
Analysts estimate Pfizer India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pfizer India and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 23.0x | XXX | XXX | XXX |
| P/E | 31.5x | XXX | XXX | XXX |
| P/E/Growth | 3.6x | XXX | XXX | XXX |
| EV/FCF | 27.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPfizer India's NTM/LTM revenue growth is 7%
Pfizer India's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Pfizer India's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pfizer India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pfizer India and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 37% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pfizer India acquired XXX companies to date.
Last acquisition by Pfizer India was XXXXXXXX, XXXXX XXXXX XXXXXX . Pfizer India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pfizer India founded? | Pfizer India was founded in 1950. |
| Where is Pfizer India headquartered? | Pfizer India is headquartered in India. |
| How many employees does Pfizer India have? | As of today, Pfizer India has 1.7K+ employees. |
| Is Pfizer India publicy listed? | Yes, Pfizer India is a public company listed on NSE. |
| What is the stock symbol of Pfizer India? | Pfizer India trades under PFIZER ticker. |
| When did Pfizer India go public? | Pfizer India went public in 1999. |
| Who are competitors of Pfizer India? | Similar companies to Pfizer India include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pfizer India? | Pfizer India's current market cap is $2.2B |
| What is the current revenue of Pfizer India? | Pfizer India's last 12-month revenue is $261M. |
| What is the current EBITDA of Pfizer India? | Pfizer India's last 12-month EBITDA is $79.2M. |
| What is the current EV/Revenue multiple of Pfizer India? | Current revenue multiple of Pfizer India is 7.3x. |
| What is the current EV/EBITDA multiple of Pfizer India? | Current EBITDA multiple of Pfizer India is 24.1x. |
| What is the current revenue growth of Pfizer India? | Pfizer India revenue growth between 2023 and 2024 was -10%. |
| Is Pfizer India profitable? | Yes, Pfizer India is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
